The Anti-Mullerian Hormone Levels In Polycystic Ovary Syndrome And Its Relation To Body Mass Index

BACKGROUND:
Anti-mullerian hormone level reflects the ovarian follicular reserve and considered as sensitive marker of ovarian aging. Although the ultimate pathogenesis of polycystic ovary syndrom remains obscure, the distinictive feature is a failure of follicular maturation resulting in anovulation and accumulation of pre-antral and small antral follicles which contribute significantly to the production of anti-mullerian hormone.
OBJECTIVE:
To evaluate the anti-mullerian hormone levels in polycystic ovary syndrome women and to explore its relation with body mass index.
STUDY DESIGN:
Cross section study.
Setting: Department of Gynecology and Obstetrics at Al-Elwiya Maternity Teaching Hospital.
MATERIALS AND METHODS:
One hunderd women suffering from polycystic ovary syndrom (18-37 years old) were included in the study and arranged in three groups according to their body mass index: first group, 30 of them, were having normal body weight (body mass index 18.5 to 24.9kg/m²) and second group, 59 participants withbody mass index 25 to 29.9kg/m² and third group, 11 women, their body mass index ≥ 30kg/m². Blood sample was collected from them after taking a detailed history and assessment according to the questioner form and the results were compared among the groups.
RESULTS:
Increase in body mass index is found to be accompanied with decrease in anti-mullerian hormone levels (P <0.05), with mean anti-mullerian hormone level significantly decreases as body mass shifts up from normal to overweight to obesity (8.5, 6.4 & 4.4 ng/mL respectively) (P <0.05). Anti-mullerian hormone level did not significantly correlate with age of those women (P >0.05).
CONCLUSION:
An inverse correlation had been found between anti-mullerian hormone levels and body mass index in women with polycystic ovary syndrome.

Keywords

References

Artemis K., Christos V., Dimitrios P. The clinical significance of anti-Müllerian hormone evaluation in gynecological endocrinology.Hormones.2011;10:95-103.
Fauser BC,Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, Carmina E, Chang J, Yildiz BO, Laven JS, Boivin J, Petraglia F, Wijeyeratne CN, Norman RJ, Dunaif A, Franks S, Wild RA, Dumesic D, Barnhart K. Consensus on women health aspects of polycystic ovary syndrome (PCOS). Hum Reprod. 2012; 27:14-24.
Fauser BC,Diedrich K, Bouchard P, Domínguez F, Matzuk M, Franks S, Hamamah S, Simón C, Devroey P, Ezcurra D, Howles CM. Contemporary genetic technologies and female reproduction. Hum Reprod Update.2011;17:829-47.
Tsilchorozidou T, Overton C, Conway GS. The pathophysiology of polycystic ovary syndrome. Clin Endocrinol(oxf). 2004; 60:1–17.
The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19-25.
Dewailly D, Barbotin A L, Dumont A. Role of Anti-Müllerian Hormone in the Pathogenesis of Polycystic Ovary Syndrome. Front Endocrinol (Lausanne) 2020;11:641.
Pellat L, Hanna L, Brinmat M, Galea R, Brain H, Whitehead S. Granulosa cell production of anti Müllerian hormone is increased in polycystic ovaries. J Clin Endocrinol Metab. 2007; 92:240-45.
Seifer D, MacLaughlin D. Müllerian inhibiting substance is an ovarian growth factor of emerging significance. Fertil Steril. 2007;88:539-46.
Aubuchon M, Burney RO, schust DJ, Yao MW.Infertility and assisted reproductive technology. In: Berek JS (Ed.). Berek & Novak's gynecology. 15^th Philadelphia: Lippincott Williams and Wilkins; 2012:1079.
Laven JS, Mulders AG, Visser JA, Themmen AP, Dejong FH, Fauser BC. Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab. 2004; 89:318-23.
Alebic MS, Stojanovic N, Duhamel A, Dewailly D. The phenotypic diversity in per-follicle anti-mullerian hormone production in polycystic ovary syndrome. Hum Reprod. 2015; 30:1927-33.
Freeman EW, Gracia CR, Sammel MD, Lin H, Lim LC, Strauss JF 3rd. Association of anti-Müllerian hormone levels with obesity in late reproductive-age women. Fertil Steril. 2007; 87:101–6

13. Mei-Jou Chen,Wei-Shiung Yang, Chi-Ling Chen,et al,,.The relation between anti-mullerian hormone, androgen and insulin resistance on the number of antral follicles in women with polycystic ovary syndrome. Hum Reprod.2008; 23:952-57.

Piouka A, Farmakiotis D, Katsikis I, Macut D, Gerou S, Panidis D. Anti-Müllerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am J Physiol Endocrinol Metab. 2009; 296:E238-43.
Park AS, Lawson MA, Chuan SS, Oberfield SE, Hoeger KM, Witchel SF, chang RJ. Serum anti-mullerian hormone concentrations are elevated in oligomenorrheic girls without evidence of hyperandrogenism. J Clin Endocrinol Metab. 2010;95:1786-92.
Kriseman M, Mills C, Kovanci E, Sangi-haghpeykar H, Gibbons W. Anti-mullerian hormone levels are inversely associated with body mass index (BMI) in women with polycystic ovary syndrome. J assist Reprod Genet. 2015; 32:1313-16.
Siow Y, Kives S, Hertweck P, Perlman S, Fallat ME. Serum Mullerian-inhibiting substance levels in adolescent girls with normal menstrual cycles or with polycystic ovary syndrome. Fertil Steril. 2005; 84:938–44.
Cengiz H,Ekin M, Dagdeviren H, Yildiz Ş, Kaya C, Kanawati A. Comparison of serum anti-Müllerian hormone levels in normal weight and overweight-obese adolescent patients with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2014; 180:46-50.
Luo E, Zhang J, Song J, Feng D, Meng Serum Anti-Müllerian Hormone Levels Were Negatively Associated With Body Fat Percentage in PCOS Patients. Front Endocrinol (Lausanne). 2021 ;12:659717.
Pigny P, Merlen E, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S, Dewailly D. Elevated serum level of anti-Müllerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab. 2003; 88:5957–62.
Piltonen T, Morin-Papunen L, Koivunen R, Perheentupa A. Serum anti-Mullerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Hum Reprod. 2005;20: 1820-26
Jawad AK, Ali MS. Anti mullerian Hormone Serum concentrations in normoovulatory and anovulatory women of reproductive age. JSMC. 2013;3:117-24.